Free Trial

Adagene (ADAG) Competitors

Adagene logo
$1.90 +0.02 (+1.28%)
As of 04:00 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

ADAG vs. ARCT, MBX, CMPX, TERN, HUMA, PRTA, HRTX, AMRN, PRME, and SNDL

Should you be buying Adagene stock or one of its competitors? The main competitors of Adagene include Arcturus Therapeutics (ARCT), MBX Biosciences (MBX), Compass Therapeutics (CMPX), Terns Pharmaceuticals (TERN), Humacyte (HUMA), Prothena (PRTA), Heron Therapeutics (HRTX), Amarin (AMRN), Prime Medicine (PRME), and SNDL (SNDL). These companies are all part of the "pharmaceutical products" industry.

Adagene vs. Its Competitors

Adagene (NASDAQ:ADAG) and Arcturus Therapeutics (NASDAQ:ARCT) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their earnings, valuation, dividends, risk, profitability, analyst recommendations, media sentiment and institutional ownership.

In the previous week, Arcturus Therapeutics had 1 more articles in the media than Adagene. MarketBeat recorded 5 mentions for Arcturus Therapeutics and 4 mentions for Adagene. Arcturus Therapeutics' average media sentiment score of 0.46 beat Adagene's score of 0.32 indicating that Arcturus Therapeutics is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Adagene
0 Very Positive mention(s)
2 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
Arcturus Therapeutics
1 Very Positive mention(s)
1 Positive mention(s)
1 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Neutral

9.5% of Adagene shares are owned by institutional investors. Comparatively, 94.5% of Arcturus Therapeutics shares are owned by institutional investors. 21.2% of Adagene shares are owned by insiders. Comparatively, 16.6% of Arcturus Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Adagene has a beta of 0.74, meaning that its share price is 26% less volatile than the S&P 500. Comparatively, Arcturus Therapeutics has a beta of 2.27, meaning that its share price is 127% more volatile than the S&P 500.

Adagene has higher earnings, but lower revenue than Arcturus Therapeutics.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Adagene$100K913.93-$33.42MN/AN/A
Arcturus Therapeutics$152.31M2.58-$80.94M-$2.53-5.72

Adagene has a net margin of 0.00% compared to Arcturus Therapeutics' net margin of -47.47%. Adagene's return on equity of 0.00% beat Arcturus Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
AdageneN/A N/A N/A
Arcturus Therapeutics -47.47%-27.41%-19.01%

Adagene currently has a consensus price target of $8.00, indicating a potential upside of 312.37%. Arcturus Therapeutics has a consensus price target of $54.00, indicating a potential upside of 272.93%. Given Adagene's higher possible upside, equities research analysts clearly believe Adagene is more favorable than Arcturus Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Adagene
0 Sell rating(s)
1 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
2.50
Arcturus Therapeutics
0 Sell rating(s)
0 Hold rating(s)
8 Buy rating(s)
1 Strong Buy rating(s)
3.11

Summary

Arcturus Therapeutics beats Adagene on 8 of the 15 factors compared between the two stocks.

Get Adagene News Delivered to You Automatically

Sign up to receive the latest news and ratings for ADAG and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ADAG and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

ADAG vs. The Competition

MetricAdageneMED IndustryMedical SectorNASDAQ Exchange
Market Cap$88.57M$2.96B$5.56B$9.04B
Dividend YieldN/A2.42%5.25%4.03%
P/E RatioN/A8.0519.5820.23
Price / Sales913.93296.11442.27127.79
Price / CashN/A42.7337.5058.41
Price / Book1.707.748.085.60
Net Income-$33.42M-$54.96M$3.16B$248.43M
7 Day Performance2.92%6.04%3.77%5.15%
1 Month Performance-1.02%4.47%3.90%7.62%
1 Year Performance-29.71%6.12%34.22%21.56%

Adagene Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
ADAG
Adagene
2.0509 of 5 stars
$1.94
+3.2%
$8.00
+312.4%
-31.6%$88.57M$100K0.00260Gap Up
ARCT
Arcturus Therapeutics
2.6893 of 5 stars
$13.01
-2.4%
$53.50
+311.2%
-34.2%$361.52M$152.31M-5.14180
MBX
MBX Biosciences
2.55 of 5 stars
$11.41
+6.1%
$37.50
+228.7%
N/A$359.31MN/A0.0036
CMPX
Compass Therapeutics
2.6547 of 5 stars
$2.60
+1.6%
$13.13
+404.8%
+216.4%$354M$850K-6.3420
TERN
Terns Pharmaceuticals
3.7656 of 5 stars
$3.73
-2.6%
$15.63
+318.9%
-34.4%$334.50MN/A-3.4240
HUMA
Humacyte
2.907 of 5 stars
$2.09
-1.4%
$11.71
+460.5%
-56.6%$328.85M$1.57M-3.03150News Coverage
Analyst Forecast
PRTA
Prothena
3.0657 of 5 stars
$6.07
-0.2%
$31.50
+418.9%
-68.1%$327.27M$135.16M-2.92130
HRTX
Heron Therapeutics
3.9299 of 5 stars
$2.07
-3.3%
$5.00
+141.5%
-24.0%$326.49M$144.29M-34.50300News Coverage
AMRN
Amarin
0.7096 of 5 stars
$16.22
+3.2%
$12.00
-26.0%
+23.8%$325.31M$228.61M-4.46360High Trading Volume
PRME
Prime Medicine
4.0811 of 5 stars
$2.47
+2.1%
$10.08
+308.2%
-19.2%$324.30M$3.85M-1.20234Positive News
Options Volume
High Trading Volume
SNDL
SNDL
3.6638 of 5 stars
$1.21
-1.6%
$3.63
+199.6%
-27.9%$323.21M$671.81M-4.172,516News Coverage
Gap Down

Related Companies and Tools


This page (NASDAQ:ADAG) was last updated on 7/10/2025 by MarketBeat.com Staff
From Our Partners